Polyrizon Ltd. Secures $3.5 Million in Registered Direct Offering and Private Placement

Polyrizon Ltd. (NASDAQ: PLRZ), a pre‑clinical‑stage biotechnology firm headquartered in Ra’anana, Israel, announced the completion of a registered direct offering and a concurrent private placement on 8 April 2026. The transaction, which involved a single institutional investor, generated aggregate gross proceeds of approximately $3.5 million for the company.

Offering Structure

The company sold 388,888 units—each unit comprising one ordinary share (or one pre‑funded warrant to purchase an ordinary share) and one common warrant to purchase an ordinary share. The offering price was set at $9.00 per unit (or $8.99999 per pre‑funded unit), reflecting the unit price minus the exercise price of $0.00001 per pre‑funded warrant. Both the registered direct offering and the private placement were executed simultaneously, ensuring a streamlined capital‑raising process.

Capital Allocation and Cash Position

The proceeds are earmarked to bolster Polyrizon’s cash reserves and support the advancement of its proprietary intranasal therapy pipeline. The company’s current market capitalization stands at $19,950,000 (USD), and its most recent close on 5 April 2026 was $12.30 per share. With the new funding, the firm is better positioned to pursue upcoming clinical milestones and expand its research and development activities.

Focus on Intranasal Protective Solutions

Polyrizon’s core technology centers on a hydrogel‑based intranasal platform designed to create a protective barrier within the nasal cavity. This barrier aims to shield patients from airborne viruses, allergens, and other harmful particles, thereby reducing exposure and infection risk. The company’s pipeline includes:

  • Intranasal protective gels for viral defense – designed to neutralise or block airborne viral particles before they reach the respiratory tract.
  • Allergen‑preventive formulations – intended to reduce the impact of airborne allergens on susceptible individuals.
  • Broader applications – the platform may be adapted to address additional respiratory and allergy‑related conditions.

Strategic Partnerships

In line with its development strategy, Polyrizon has signed an agreement with a leading global preclinical contract research organization (CRO). The partnership will support the clinical pathway of its programs, with studies slated to commence in the second quarter of 2026. This collaboration underscores the company’s commitment to progressing from pre‑clinical research toward eventual clinical validation.

Market Context

Polyrizon operates within the health‑care sector and trades on Nasdaq under the ticker PLRZ. Its 52‑week trading range highlights significant volatility: a high of $2,235.00 (recorded on 4 May 2025) and a low of $2.88 (recorded on 25 Nov 2025). Despite this fluctuation, the recent capital raise demonstrates investor confidence in the company’s innovative intranasal solutions and its potential to address unmet needs in respiratory and allergy care.

In summary, Polyrizon Ltd.’s successful closing of a $3.5 million registered direct offering and private placement marks a pivotal step in its journey from pre‑clinical research to potential clinical application. The infusion of capital will enable the firm to accelerate the development of its intranasal protective platform, forge critical partnerships, and strengthen its position within the competitive biotechnology landscape.